A Single Arm, Open-label Multicenter Phase II Trial of Temsirolimus in Patients With Relapsed/Recurrent Squamous Cell Cancer of the Head and Neck (HNSCC).
Phase of Trial: Phase II
Latest Information Update: 19 Dec 2014
At a glance
- Drugs Temsirolimus (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- Acronyms TEMHEAD
- 07 Jul 2012 Status changed from recruiting to completed as reported in the European Clinical Trials Database record.
- 07 Jul 2012 Pfizer added as associations as reported in the European Clinical Trials Database record.
- 16 Nov 2011 Actual initiation date changed from Jun 2010 to 9 Feb 2010 as reported by European Clinical Trials Database.